The combination of a recently approved blood test for the detection of Alzheimer’s disease, combined with two medications that slow the progression of the disease, is drastically improving outcomes ...
Surprisingly, early-stage CTE showed no link to cognitive decline In A Nutshell CTE severity had no link to depression, ...
・HSBC cut Novo Nordisk to ‘Hold’ after its EVOKE Alzheimer’s trials showed no slowing of disease progression versus placebo. ・JPMorgan called the sharp market reaction an “overreaction,” noting little ...
Novo Nordisk encountered a significant disappointment this week when the company announced that late-stage trials of Rybelsus failed to demonstrate effectiveness in slowing cognitive decline among ...
Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results